CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine

NEXT STORY
Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
PREV STORY
Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML)

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from ...

author_avatar
NASDAQ Market News

ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan

author_avatar
NASDAQ Market News

Central Venous Catheter Market To Witness Impressive Expansion, Reflecting A 5.1% CAGR During 2016-2026

Global Central Venous Catheter Market Anticipated to be Valued at US$ 1,108.4 Mn by ...

author_avatar
NASDAQ Market News